4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Type 2 Diabetes by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1950 ongoing clinical trials involving Type 2 Diabetes
Of the 1950 trials,578 trials are in Phase III
Furthermore, 533 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Type 2 Diabetes by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Type 2 Diabetes, a Metabolic Disorder. The largest number of ongoing clinical trials for Type 2 Diabetes is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Type 2 Diabetes-related drug trials.

Novo Nordisk AS: The leading ongoing Type 2 Diabetes related clinical trial sponsor

Novo Nordisk AS is the top sponsor for Type 2 Diabetes-related ongoing clinical trials.

Eli Lilly and Co , University of Texas Health Science Center at San Antonio, Tabriz University of Medical Sciences and Mayo Clinic are among other notable clinical trial sponsors involved in Type 2 Diabetes. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Type 2 Diabetes

Dulaglutide (Trulicity), Sitagliptin phosphate (Januvia/ Glactiv/ Istavel/ Tesavel/ Xelevia/ Ristaben, Fazique) and Semaglutide (Ozempic/NN-9535/NN-9931) are among the key marketed drugs involving Type 2 Diabetes.

Dulaglutide (Trulicity) is an anti-diabetic agent. It functions via Glucagon Like Peptide 1 Receptor (GLP1R) Agonist mechanism of action. Dulaglutide is formulated as solution for subcutaneous route of administration. Dulaglutide was first approved in 2014 and is marketed globally in the US, UK, China, Japan, Germany, and France by Eli Lilly and Co and its subsidiaries.

Sitagliptin phosphate (Januvia/ Glactiv/ Istavel/ Tesavel/ Xelevia/ Ristaben, Fazique) phosphate is a compound belongs to the beta amino acid derivative acts as anti-diabetic agent. It functions via Dipeptidyl Peptidase 4 Inhibitor mechanism of action. Sitagliptin phosphate is formulated as film coated tablets for oral route of administration. Sitagliptin phosphate was first approved in 2006 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Merck Sharp & Dohme Corp.